Dihydroergotamine for Migraine: Uses, Side Effects & Risks

Dihydroergotamine, commonly known as DHE, is one of the oldest migraine-specific drugs still in active clinical use, first introduced in 1943 and still considered effective for acute migraine treatment decades later.¹ It occupies an unusual niche in headache medicine: slower to work than newer triptans but with a lower rate of headache recurrence, and often reserved for the most stubborn attacks that other treatments cannot touch. Understanding how DHE works, who it is best suited for, and what to watch out for requires looking past its reputation as simply “the old drug before triptans came along.”

How DHE Works Against Migraine

DHE acts on multiple receptor systems at once, which is part of why it remains useful and part of why it was hard to design something better. It binds to serotonin receptors, particularly the 5-HT_1B and 5-HT_1D subtypes, which causes constriction of blood vessels in and around the brain.² That vasoconstriction was originally thought to be the whole story, but the picture has gotten more complicated. In lab studies, DHE also reduces levels of CGRP, a signaling molecule released by the trigeminal nerve that plays a central role in migraine pain. Pretreatment with DHE cut CGRP levels during nerve stimulation by roughly half.³

There is also evidence that DHE blocks a sensitization process in the trigeminal nerve itself. When trigeminal neurons are exposed to ATP, a chemical that ramps up pain signaling, pretreatment with DHE suppressed the resulting spike in calcium and CGRP release. This appears to work through a separate pathway involving alpha-2 adrenergic receptors, which means DHE is not just squeezing blood vessels shut but also dialing down the pain-signaling machinery at its source.⁴ This multi-pronged mechanism helps explain why DHE tends to produce a longer-lasting effect than drugs that hit only one target.

Routes of Administration

One of the practical realities of DHE is that swallowing a pill does not work well. Oral bioavailability is poor, so the drug has historically been given by injection (intravenous, intramuscular, or subcutaneous) or through the nose. Each route comes with tradeoffs in speed, convenience, and how predictably the drug gets into your bloodstream.

Nasal spray was the first non-injection option to gain widespread use. A 1-milligram nasal dose reaches peak blood levels in under an hour, but only about 38% of the drug reaches systemic circulation compared to an intramuscular injection.⁵ Variability between doses was also higher with the nasal spray, meaning one dose might hit harder than the next for the same person. That inconsistency has been a longstanding frustration.

Newer nasal delivery technology has tried to solve this problem by targeting a specific region high in the nose called the upper nasal space, which is rich in blood vessels and delivers drugs to the bloodstream more efficiently than the lower nasal passages.⁶ One device using this approach, called STS101, delivered DHE as a dry powder to the upper nasal space. In a phase 1 trial, it achieved roughly double the peak blood levels and double the total drug exposure compared to the older liquid nasal spray, with much less variability between doses. Its overall drug exposure was comparable to an intramuscular injection.⁷ Another device, called INP104, uses what its developers term Precision Olfactory Delivery to target that same upper nasal region, and clinical data similarly show rapid absorption and predictable dosing.⁸

These newer nasal options matter because they could give patients something close to injection-level drug delivery without needing a needle or a hospital visit. For a drug that has long been most effective when given intravenously in a clinical setting, that represents a meaningful shift in accessibility.

DHE Versus Triptans

The comparison that comes up most often is DHE versus sumatriptan, the prototypical triptan. The short version: sumatriptan works faster, but DHE lasts longer and the headache is far less likely to come back.

A double-blind trial comparing subcutaneous DHE (1 mg) with subcutaneous sumatriptan (6 mg) found that at two hours, about 73% of DHE-treated patients had headache relief compared to about 85% on sumatriptan. By three to four hours, the two drugs were equally effective, with roughly 85% relief in both groups. But here is where DHE pulled ahead: within 24 hours, headache recurrence was two and a half times more likely with sumatriptan than with DHE, occurring in 45% of sumatriptan patients versus about 18% of DHE patients.⁹ A review of DHE pharmacology confirmed this pattern, noting that subcutaneous DHE was inferior to subcutaneous sumatriptan for the first two hours but equally effective after three hours.¹⁰

This difference in recurrence rates is clinically important. A migraine that comes roaring back a few hours after treatment is demoralizing and functionally the same as a migraine that never went away. For people whose migraines tend to recur after triptans, DHE’s slower onset may be a worthwhile tradeoff. In lab studies comparing the two drugs on isolated human blood vessels, DHE produced contraction of cerebral arteries and veins at lower concentrations than sumatriptan, though sumatriptan achieved a higher maximum contraction in cerebral arteries.¹¹ This vascular profile may partly explain DHE’s more sustained but less dramatic effect.

Intravenous DHE for Refractory Headaches

Where DHE really earns its keep is in the hospital setting, for headaches that have refused to respond to outpatient treatments. Intravenous DHE given over multiple days is one of the standard approaches for status migrainosus, meaning a migraine attack that has lasted longer than 72 hours and will not break. It is also used for chronic migraine that has become intractable.

A study of inpatient IV DHE given over five days found that the treatment produced cumulative improvement in both headache severity and disability, with the benefit continuing to build for up to a month after discharge. Patients who received more DHE had a greater chance of becoming pain-free.¹² That cumulative, slow-building pattern is a recurring theme with DHE and one reason clinicians tend to be patient with it rather than switching after a single dose.

IV DHE has also been used for refractory cluster headache, a condition distinct from migraine but equally brutal. In a series of 97 treatment courses, complete resolution of pain during and at one month after the IV phase was achieved in about 63% of cases overall. The numbers were better for episodic cluster headache, with complete resolution in 73% of cases, while chronic cluster headache responded less well, with complete resolution in 46%.¹³ Even the chronic cluster numbers, while not spectacular, represent meaningful relief for a population that often has few remaining options.

DHE in Children and Adolescents

Pediatric headache specialists have used IV DHE for children and teenagers whose migraines or other primary headaches have become disabling and are not responding to standard treatments. The evidence base is not from randomized controlled trials but from clinical series, and the results are generally encouraging.

A retrospective review of 200 pediatric patients treated with IV DHE found that average baseline pain scores were around 8 out of 10. After treatment, pain scores dropped significantly across all headache types. About 84% of patients experienced some improvement, more than half achieved at least a 50% reduction in pain, and 18% had full resolution. The most common side effect was nausea, but it occurred in only about 6% of patients.¹⁴ Another review focused on children and adolescents with status migraine concluded that DHE was very effective at aborting these prolonged attacks and should be offered to young patients who have failed their usual treatments.¹⁵

One practical concern with inpatient IV DHE for children is cost. A study examining hospitalization outcomes found that patients who responded to treatment had shorter, less expensive stays, averaging around $5,400, compared to about $7,100 for those who did not respond. Response was correlated with receiving more doses of DHE, which suggests that committing to a full treatment course rather than cutting it short after a few doses makes a difference.¹⁶ Longer-term follow-up was less rosy: at a median of about six weeks after discharge, only about 21% of patients had sustained headache relief. This fits the broader reality that refractory headache is a chronic problem, and even a successful hospital treatment often needs to be paired with ongoing preventive strategies.

Side Effects, Nausea, and Vascular Risk

The most common side effect of DHE, and the one that most often limits treatment, is nausea. This is not subtle queasiness but the kind that can make patients want to stop treatment. A narrative review found that across phase 1 trials, nausea was minimal when peak blood levels stayed below about 2,500 pg/mL but rose sharply in a log-linear fashion above that threshold.¹⁷ This means there is a sweet spot where you get enough drug to be effective without crossing into the nausea zone, and the newer nasal delivery devices aim to stay within that window.

For inpatient IV DHE, anti-nausea medications are given as standard practice. Domperidone, a drug that blocks dopamine receptors in the gut, has been studied specifically for this purpose. In a review of over 100 consecutive admissions receiving IV DHE, domperidone at doses up to 80 mg per day was well tolerated and, combined with other anti-nausea drugs, was effective enough that no patients had nausea severe enough to force stopping the DHE.¹⁸

The more serious safety concern with DHE is vascular. As an ergot derivative, it constricts blood vessels, and in people with underlying vascular disease this can cause dangerous reductions in blood flow. DHE is contraindicated in patients with coronary artery disease, peripheral vascular disease, or uncontrolled hypertension.¹⁹ Even in people without known vascular disease, there are documented cases of serious vasospasm. One case involved a patient with Raynaud phenomenon who developed acute arterial vasospasm in the hand after 15 doses of IV DHE, losing detectable pulses in multiple fingers.²⁰ Older literature also documented cases of bilateral upper extremity ischemia when DHE was combined with heparin for blood clot prevention, a combination that fell out of favor partly because of such events.²¹

Drug interactions add another layer of caution. DHE is metabolized by the CYP3A4 enzyme system in the liver, and combining it with drugs that inhibit CYP3A4 can dangerously increase DHE levels and the risk of vasospasm. Common CYP3A4 inhibitors include certain antibiotics, antifungals, and HIV medications.²² DHE should also not be combined with triptans, since both classes constrict blood vessels and using them together raises the risk of excessive vasoconstriction.

Pregnancy

DHE is contraindicated in pregnancy. This is not a gray area. A review of migraine medications during pregnancy and lactation lists DHE alongside valproate and topiramate as having known risk for teratogenicity.²³ A population-level study examining DHE and triptan use during pregnancy found that, after adjusting for confounding factors including the migraine itself, DHE use was associated with a fourfold increased risk of premature birth. The study also found a threefold increased risk of low birth weight, though that estimate did not reach statistical significance due to small numbers.²⁴ Ergot alkaloids have historically been known to stimulate uterine contractions, which is one mechanism behind these risks. For anyone who is pregnant or planning to become pregnant, DHE should be avoided entirely, and clinicians generally switch to safer alternatives well in advance.

An Unexpected Use for Orthostatic Hypotension

DHE’s vascular effects, problematic in some contexts, have been turned to advantage in an entirely different condition: orthostatic hypotension, the drop in blood pressure that occurs when standing up, which can cause dizziness, fainting, and falls. This happens most often in people with autonomic nervous system disorders where the body fails to properly constrict blood vessels in response to gravity.

A small study of eight patients with orthostatic hypotension found that subcutaneous DHE produced a blood pressure increase in seven of them during the early morning fasting period, when symptoms are often worst. The combination of DHE with caffeine was described as a new therapeutic option for patients with severe autonomic neuropathy.²⁵ The logic is straightforward: DHE constricts veins, which prevents blood from pooling in the legs when you stand, keeping more of it flowing to the brain. A systematic review of treatments for neurogenic orthostatic hypotension lists ergot alkaloids among the alternative agents that can be considered, though it notes the quality of evidence is very low.²⁶ In practice, other drugs like midodrine and droxidopa are used far more commonly for this purpose, but DHE remains a niche option for refractory cases, particularly in countries where it is more readily available.

Why DHE Has Not Been Replaced

It would be reasonable to wonder why a drug from 1943, with its nausea problems and vascular risks, is still in use when seven different triptans and a whole generation of CGRP-targeting drugs have arrived since.²⁷ The answer lies in its unique pharmacological profile. DHE hits multiple receptor types simultaneously, including serotonin, dopamine, and adrenergic receptors. No newer drug replicates that exact combination. Its low headache recurrence rate, roughly half or less of what triptans produce, means that for patients prone to recurrence, DHE can break cycles that other drugs cannot. And for the severely refractory cases that end up in hospital, multi-day IV DHE protocols remain one of the few interventions with a track record of ending weeks-long migraine episodes.

The drug’s trajectory in recent years has been less about replacement and more about reformulation. The challenge was always that DHE worked best when injected but was impractical for routine self-treatment. The new nasal delivery technologies targeting the upper nasal space represent the field’s attempt to make DHE usable outside a hospital without sacrificing the drug levels that make it effective. If those devices succeed commercially and prove durable in long-term use, DHE could shift from being a last-resort inpatient drug to something closer to a first-line option for certain migraine patients, particularly those with high recurrence rates on triptans. The pharmacology has been sound for 80 years. What has been missing is the right delivery system.